Giulia Rioli1, Giorgio Mattei2, Caterina Bonamici3, Stefano Mancini4, Silvia Alboni5, Giuseppe Cannazza6, Paola Sena7, Luca Roncucci8, Luca Pingani9, Silvia Ferrari10, Gian Maria Galeazzi11. 1. PhD International School in Clinical and Experimental Medicine, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, via Giuseppe Campi 287, 41125, Modena, Italy; Dipartimento ad Attività Integrata Salute Mentale e Dipendenze Patologiche, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italia. giulyrioli@hotmail.it. 2. Associazione per la Ricerca in Psichiatria, Castelnuovo Rangone, Modena, Italy. giorgiomatteimd@gmail.com. 3. Section of Clinical Neurosciences, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. kate.bonamici@gmail.com. 4. Department of Internal Medicine, Guastalla Civil Hospital, Azienda USL-IRCCS di Reggio Emilia, Guastalla, Reggio Emilia, Italy. stefano.mancini@ausl.re.it. 5. Department of Life Science, University of Modena and Reggio Emilia, Modena, Italy; Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Via Campi 287, 41125, Modena, Italy. silvia.alboni@unimore.it. 6. Department of Life Science, University of Modena and Reggio Emilia, Modena, Italy. giuseppe.cannazza@unimore.it. 7. Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con Interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, University of Modena and Reggio Emilia, Modena, Italy. paola.sena@unimore.it. 8. Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, University of Modena and Reggio Emilia, Modena, Italy. luca.roncucci@unimore.it. 9. Dipartimento ad Attività Integrata Salute Mentale e Dipendenze Patologiche, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italia; Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Università degli Studi di Modena e Reggio Emilia, Modena, Italia.. luca.pingani@unimore.it. 10. Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Università degli Studi di Modena e Reggio Emilia, Modena, Italia; Dipartimento ad Attività Integrata Salute Mentale e Dipendenze Patologiche, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italia.. silferra@unimore.it. 11. Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Università degli Studi di Modena e Reggio Emilia, Modena, Italia; Dipartimento ad Attività Integrata Salute Mentale e Dipendenze Patologiche, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italia.. gianmaria.galeazzi@unimore.it.
Abstract
BACKGROUND AND AIM OF THE WORK: To explore gender differences in patients suffering from anxious-depressive symptoms, Metabolic Syndrome (MetS) and Colorectal Adenomas (CRAs) in a sample of outpatients undergoing colonoscopy for screening purposes. METHODS: Cross-sectional study. 126 consecutive outpatients of both sexes undergoing colonoscopy for non-specific abdominal symptoms between January 2015 and June 2021 at the Modena Policlinico General Hospital (Modena, Northern Italy) were enrolled. MetS was diagnosed according to ATPIII and IDF criteria. Anxiety and depression were assessed with the Hospital Anxiety and Depression Scale (HADS), while the Temperament and Character Inventory (TCI) was used to study personality. The SF-36 was also included as a measure of quality of life perception. RESULTS: Among 126 outpatients (51.60% male) undergoing colonoscopy, 51 (44%) had CRAs, 54 (47%) MetS, 41 (41.40%) anxiety symptoms, 22 (22.20%) depressive symptoms and 13 (13.10%) combined anxious-depressive symptoms. HADS-Anxiety (t=2.68, p=0.01) and TCI Reward Dependence (TCI-RD) (t=3.01, p=0.00) mean scores were significantly higher in women; conversely, SF-36 Mental Component Summary scores were higher in men. CRAs were significantly prevalent in men (χ2=9.32, p=0.00) and were statistically significantly associated with male sex at the univariate logistic regression analysis (OR=3.27; p<0.01). At the multivariate logistic regression, diastolic hypertension (p<0.01) was positively associated with male sex, while TCI-RD (p=0.04) and HDL hypocholesterolemia (p=0.02) were inversely associated with male sex. CONCLUSIONS: Several significant gender differences in anxious-depressive symptoms, MetS and CRAs were found. These preliminary data suggest the need to consider gender specificities while implementing therapeutic, diagnostic, and preventive strategies.
BACKGROUND AND AIM OF THE WORK: To explore gender differences in patients suffering from anxious-depressive symptoms, Metabolic Syndrome (MetS) and Colorectal Adenomas (CRAs) in a sample of outpatients undergoing colonoscopy for screening purposes. METHODS: Cross-sectional study. 126 consecutive outpatients of both sexes undergoing colonoscopy for non-specific abdominal symptoms between January 2015 and June 2021 at the Modena Policlinico General Hospital (Modena, Northern Italy) were enrolled. MetS was diagnosed according to ATPIII and IDF criteria. Anxiety and depression were assessed with the Hospital Anxiety and Depression Scale (HADS), while the Temperament and Character Inventory (TCI) was used to study personality. The SF-36 was also included as a measure of quality of life perception. RESULTS: Among 126 outpatients (51.60% male) undergoing colonoscopy, 51 (44%) had CRAs, 54 (47%) MetS, 41 (41.40%) anxiety symptoms, 22 (22.20%) depressive symptoms and 13 (13.10%) combined anxious-depressive symptoms. HADS-Anxiety (t=2.68, p=0.01) and TCI Reward Dependence (TCI-RD) (t=3.01, p=0.00) mean scores were significantly higher in women; conversely, SF-36 Mental Component Summary scores were higher in men. CRAs were significantly prevalent in men (χ2=9.32, p=0.00) and were statistically significantly associated with male sex at the univariate logistic regression analysis (OR=3.27; p<0.01). At the multivariate logistic regression, diastolic hypertension (p<0.01) was positively associated with male sex, while TCI-RD (p=0.04) and HDL hypocholesterolemia (p=0.02) were inversely associated with male sex. CONCLUSIONS: Several significant gender differences in anxious-depressive symptoms, MetS and CRAs were found. These preliminary data suggest the need to consider gender specificities while implementing therapeutic, diagnostic, and preventive strategies.
Authors: M V Mendlowicz; G Jean-Louis; J C Gillin; H S Akiskal; L M Furlanetto; M H Rapaport; J R Kelsoe Journal: J Psychiatr Res Date: 2000 May-Jun Impact factor: 4.791
Authors: Julie K K Vishram; Anders Borglykke; Anne H Andreasen; Jørgen Jeppesen; Hans Ibsen; Torben Jørgensen; Luigi Palmieri; Simona Giampaoli; Chiara Donfrancesco; Frank Kee; Giuseppe Mancia; Giancarlo Cesana; Kari Kuulasmaa; Veikko Salomaa; Susana Sans; Jean Ferrieres; Jean Dallongeville; Stefan Söderberg; Dominique Arveiler; Aline Wagner; Hugh Tunstall-Pedoe; Wojciech Drygas; Michael H Olsen Journal: PLoS One Date: 2015-05-15 Impact factor: 3.240
Authors: JungHyun Lee; Kun Sei Lee; Hyeongsu Kim; Hyoseon Jeong; Min-Jung Choi; Hai-Won Yoo; Tae-Hwa Han; Hyunjung Lee Journal: Environ Health Prev Med Date: 2020-02-19 Impact factor: 3.674